Evidence map›Paper›PMID 34629825›Full record

ArticleWorld journal of gastroenterology2021

Urotensin II levels in patients with inflammatory bowel disease.

Damir Alicic, Dinko Martinovic, Doris Rusic, Piero Marin Zivkovic, Ivana Tadin Hadjina, Marino Vilovic, Marko Kumric, Daria Tokic, Daniela Supe-Domic, Slaven Lupi-Ferandin and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Molecular analysis of duodenal eosinophilia.The Journal of allergy and clinical immunology · 2023
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Damir AlicicDepartment of Gastroenterology, University Hospital of Split, Split 21000, Croatia.
Dinko MartinovicDepartment of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia.
Doris RusicDepartment of Pharmacy, University of Split School of Medicine, Split 21000, Croatia.
Piero Marin ZivkovicDepartment of Gastroenterology, University Hospital of Split, Split 21000, Croatia.
Ivana Tadin HadjinaDepartment of Gastroenterology, University Hospital of Split, Split 21000, Croatia.
Marino VilovicDepartment of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia.
Marko KumricDepartment of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia.
Daria TokicDepartment of Anesthesiology and Intensive care, University Hospital of Split, Split 21000, Croatia.
Daniela Supe-DomicDepartment of Health Studies, University of Split, Split 21000, Croatia.
Slaven Lupi-FerandinDepartment of Maxillofacial Surgery, University Hospital of Split, Split 21000, Croatia.
Josko BozicDepartment of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia. josko.bozic@mefst.hr.
University of Split · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with inflammatory bowel disease (IBD) are associated with increased cardiovascular risk and have increased overall cardiovascular burden. On the other hand, urotensin II (UII) is one of the most potent vascular constrictors with immunomodulatory effect that is connected with a number of different cardiometabolic disorders as well. Furthermore, patients with ulcerative colitis have shown increased expression of urotensin II receptor in comparison to healthy controls. Since the features of IBD includes chronic inflammation and endothelial dysfunction as well, it is plausible to assume that there is connection between increased cardiac risk in IBD and UII.

aimTo determine serum UII levels in patients with IBD and to compare them to control subjects, as well as investigate possible associations with relevant clinical and biochemical parameters.

methodsThis cross sectional study consecutively enrolled 50 adult IBD patients (26 with Crohn's disease and 24 with ulcerative colitis) and 50 age and gender matched controls. Clinical assessment was performed by the same experienced gastroenterologist according to the latest guidelines. Ulcerative Colitis Endoscopic Index of Severity and Simple Endoscopic Score for Crohn's Disease were used for endoscopic evaluation. Serum levels of UII were determined using the enzyme immunoassay kit for human UII, according to the manufacturer's instructions.

resultsIBD patients have significantly higher concentrations of UII when compared to control subjects (7.57 ± 1.41

conclusionIt is possible that UII is involved in the complex pathophysiology of cardiovascular complications in IBD patients, and its purpose should be investigated in further studies.

Indexed as

Colitis, UlcerativeInflammatory Bowel DiseasesUrotensinsAdultCross-Sectional StudiesHumansurotensin IIUrotensinsCardiovascular riskCrohn’s diseaseEndoscopic activityInflammatory bowel diseaseUlcerative colitisUrotensin II

Identifiers

PMID34629825
PMCPMC8476337
OpenAlexW3202838376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.